Publications

FEATURED PUBLICATIONS

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

Invivoscribe Marketing2024-06-21T12:55:12-07:00June 21st, 2024|

VIEW PUBLICATION ⟶

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Invivoscribe Marketing2024-05-02T11:47:00-07:00May 2nd, 2024|

VIEW PUBLICATION ⟶

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Invivoscribe Marketing2024-03-26T13:55:01-07:00March 20th, 2024|

VIEW PUBLICATION ⟶

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

Invivoscribe Marketing2024-03-26T13:50:51-07:00March 19th, 2024|

VIEW PUBLICATION ⟶

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Invivoscribe Marketing2024-03-03T11:41:21-08:00March 1st, 2024|

VIEW PUBLICATION ⟶

Leveraging Standardized MRD Assays to Guide CLL Treatment

wmm2024-01-25T10:44:11-08:00January 25th, 2024|

VIEW PUBLICATION ⟶

LATEST PUBLICATIONS

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

VIEW PUBLICATION ⟶

June 21st, 2024|

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

VIEW PUBLICATION ⟶

May 2nd, 2024|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

VIEW PUBLICATION ⟶

March 20th, 2024|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

VIEW PUBLICATION ⟶

March 19th, 2024|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

VIEW PUBLICATION ⟶

March 1st, 2024|

Leveraging Standardized MRD Assays to Guide CLL Treatment

VIEW PUBLICATION ⟶

January 25th, 2024|

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

VIEW PUBLICATION ⟶

March 23rd, 2023|

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

VIEW PUBLICATION ⟶

March 7th, 2023|

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

VIEW PUBLICATION ⟶

March 2nd, 2023|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

VIEW PUBLICATION ⟶

November 15th, 2022|

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

VIEW PUBLICATION ⟶

June 4th, 2022|

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

VIEW PUBLICATION ⟶

May 30th, 2022|

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma

VIEW PUBLICATION ⟶

May 3rd, 2022|

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

VIEW PUBLICATION ⟶

January 4th, 2022|

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL

VIEW PUBLICATION ⟶

December 28th, 2021|

Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx

VIEW PUBLICATION ⟶

December 8th, 2021|

Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform

VIEW PUBLICATION ⟶

November 5th, 2021|

Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing

VIEW PUBLICATION ⟶

June 24th, 2021|

Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma

VIEW PUBLICATION ⟶

April 28th, 2021|

Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

VIEW PUBLICATION ⟶

April 20th, 2021|

Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers

VIEW PUBLICATION ⟶

November 25th, 2020|

Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status

VIEW PUBLICATION ⟶

November 22nd, 2020|

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

VIEW PUBLICATION ⟶

November 17th, 2020|

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

VIEW PUBLICATION ⟶

October 30th, 2020|

Plasticity of the human IgM repertoire in response to long‐term spaceflight

VIEW PUBLICATION ⟶

October 13th, 2020|

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

VIEW PUBLICATION ⟶

October 8th, 2020|

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

VIEW PUBLICATION ⟶

August 27th, 2020|

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment

VIEW PUBLICATION ⟶

July 22nd, 2020|

Evaluation of the polymerase chain reaction–based T-cell receptor β clonality test in the diagnosis of early mycosis fungoides

VIEW PUBLICATION ⟶

June 8th, 2020|

Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing

VIEW PUBLICATION ⟶

May 19th, 2020|

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

VIEW PUBLICATION ⟶

May 6th, 2020|

Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

VIEW PUBLICATION ⟶

May 1st, 2020|

Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status

VIEW PUBLICATION ⟶

April 1st, 2020|

Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complications

VIEW PUBLICATION ⟶

March 1st, 2020|

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

VIEW PUBLICATION ⟶

February 6th, 2020|

Monitoring minimal residual disease in the bone marrow using next generation sequencing

VIEW PUBLICATION ⟶

January 17th, 2020|

Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequence

VIEW PUBLICATION ⟶

November 13th, 2019|

Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications

VIEW PUBLICATION ⟶

October 15th, 2019|

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

VIEW PUBLICATION ⟶

October 1st, 2019|

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

VIEW PUBLICATION ⟶

June 6th, 2019|

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

VIEW PUBLICATION ⟶

March 21st, 2019|

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

VIEW PUBLICATION ⟶

August 25th, 2018|

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

VIEW PUBLICATION ⟶

August 22nd, 2018|

Clinical-scale Rapid Autologous BK-virus Specific T Cell Line generation from Kidney Transplant Recipients with Active Viremia for Adoptive Immunotherapy

VIEW PUBLICATION ⟶

November 11th, 2017|

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

VIEW PUBLICATION ⟶

August 9th, 2017|

Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia

VIEW PUBLICATION ⟶

July 3rd, 2017|

In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis

VIEW PUBLICATION ⟶

June 20th, 2017|

Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients

VIEW PUBLICATION ⟶

June 17th, 2017|

T and B cell clonal expansion in Ras associated lymphoproliferative disease (RALD) as revealed by next generation sequencing

VIEW PUBLICATION ⟶

May 30th, 2017|

Molecular pathology diagnosis of diffuse large B cell lymphoma using BIOMED-2 clonal gene rearrangements

VIEW PUBLICATION ⟶

April 27th, 2017|

A Small Case Series of Intravascular Large B-Cell Lymphoma with Unexpected Findings: Subset of Cases with Concomitant Extravascular Central Nervous System (CNS) Involvement Mimicking Primary CNS Lymphoma

VIEW PUBLICATION ⟶

April 17th, 2017|

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

VIEW PUBLICATION ⟶

October 31st, 2016|

Breast Implant-Associated Anaplastic Large Cell Lymphoma: Two Distinct Clinicopathological Variants with Different Outcomes

VIEW PUBLICATION ⟶

February 1st, 2016|

Discordant Lymphoma Consisting of Mediastinal Large B-Cell Lymphoma and Nodular Sclerosis Hodgkin Lymphoma in the Right Supraclavicular Lymph Nodes: A Case Report

VIEW PUBLICATION ⟶

December 29th, 2015|

Molecular Genetic Data Favoring a Sequential Clonal Transformation of a Large B Cell Lymphoma into an Anaplastic Large T Cell Lymphoma, ALK-Negative

VIEW PUBLICATION ⟶

December 1st, 2015|

Mucosal CD30-Positive T-Cell Lymphoproliferative Disorder Arising in the Oral Cavity Following Dental Implants

VIEW PUBLICATION ⟶

August 10th, 2015|

Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia

VIEW PUBLICATION ⟶

March 18th, 2015|

Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas

VIEW PUBLICATION ⟶

August 15th, 2014|

Immunoblastic Follicular Lymphoma: A Very Unusual Transformation of Low-Grade Follicular Lymphoma

VIEW PUBLICATION ⟶

August 13th, 2014|

The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies

VIEW PUBLICATION ⟶

April 5th, 2014|

Clonality Of Multiple Distinct Lymphoproliferative Disorders Occurring Within Individual HIV+ Patients

VIEW PUBLICATION ⟶

November 15th, 2013|

Hydroa Vacciniforme-like Lymphoma: A Chronic EBV+ Lymphoproliferative Disorder with Risk to Develop a Systemic Lymphoma

VIEW PUBLICATION ⟶

October 31st, 2013|

Paediatric and Adolescent Elevated Conjunctival Lesions in the Plical Area: Lymphoma or Reactive Lymphoid Hyperplasia?

VIEW PUBLICATION ⟶

October 25th, 2013|

Diagnostic Utility of a Clonality Test for Lymphoproliferative Diseases in Koreans Using the BIOMED-2 PCR Assay

VIEW PUBLICATION ⟶

October 25th, 2013|

Dried Blood Spot Sampling for Detection of Monoclonal Immunoglobulin Gene Rearrangement

VIEW PUBLICATION ⟶

August 13th, 2013|

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations

VIEW PUBLICATION ⟶

October 26th, 2012|

A Practical Approach to Diagnostic Ig/TCR Clonality Evaluation in Clinical Pathology

VIEW PUBLICATION ⟶

January 11th, 2012|

Multiple Clonal Ig/TCR Products: Implications for Interpretation of Clonality Findings

VIEW PUBLICATION ⟶

December 10th, 2011|

Application of cost–effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia

VIEW PUBLICATION ⟶

March 30th, 2011|

Molecular Diagnostics of Hematologic Malignancies

VIEW PUBLICATION ⟶

September 2nd, 2009|

IMGT/GeneInfo: T cell receptor gamma TRG and delta TRD genes in database give access to all TR potential V(D)J recombinations

VIEW PUBLICATION ⟶

April 26th, 2006|

IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V–J and V–D–J JUNCTIONs

VIEW PUBLICATION ⟶

August 4th, 2004|

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

VIEW PUBLICATION ⟶

June 21st, 2024|

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

VIEW PUBLICATION ⟶

May 2nd, 2024|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

VIEW PUBLICATION ⟶

March 20th, 2024|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

VIEW PUBLICATION ⟶

March 19th, 2024|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

VIEW PUBLICATION ⟶

March 1st, 2024|

Leveraging Standardized MRD Assays to Guide CLL Treatment

VIEW PUBLICATION ⟶

January 25th, 2024|

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

VIEW PUBLICATION ⟶

March 23rd, 2023|

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

VIEW PUBLICATION ⟶

March 7th, 2023|

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

VIEW PUBLICATION ⟶

March 2nd, 2023|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

VIEW PUBLICATION ⟶

November 15th, 2022|

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

VIEW PUBLICATION ⟶

June 4th, 2022|

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

VIEW PUBLICATION ⟶

May 30th, 2022|

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma

VIEW PUBLICATION ⟶

May 3rd, 2022|

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

VIEW PUBLICATION ⟶

January 4th, 2022|

Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma

VIEW PUBLICATION ⟶

April 28th, 2021|

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL

VIEW PUBLICATION ⟶

December 28th, 2021|

Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx

VIEW PUBLICATION ⟶

December 8th, 2021|

Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform

VIEW PUBLICATION ⟶

November 5th, 2021|

Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing

VIEW PUBLICATION ⟶

June 24th, 2021|

Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

VIEW PUBLICATION ⟶

April 20th, 2021|

Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers

VIEW PUBLICATION ⟶

November 25th, 2020|

Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status

VIEW PUBLICATION ⟶

November 22nd, 2020|

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

VIEW PUBLICATION ⟶

November 17th, 2020|

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

VIEW PUBLICATION ⟶

October 30th, 2020|

Plasticity of the human IgM repertoire in response to long‐term spaceflight

VIEW PUBLICATION ⟶

October 13th, 2020|

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

VIEW PUBLICATION ⟶

October 8th, 2020|

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

VIEW PUBLICATION ⟶

August 27th, 2020|

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment

VIEW PUBLICATION ⟶

July 22nd, 2020|

Evaluation of the polymerase chain reaction–based T-cell receptor β clonality test in the diagnosis of early mycosis fungoides

VIEW PUBLICATION ⟶

June 8th, 2020|

Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing

VIEW PUBLICATION ⟶

May 19th, 2020|

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

VIEW PUBLICATION ⟶

May 6th, 2020|

Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

VIEW PUBLICATION ⟶

May 1st, 2020|

Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status

VIEW PUBLICATION ⟶

April 1st, 2020|

Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complications

VIEW PUBLICATION ⟶

March 1st, 2020|

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

VIEW PUBLICATION ⟶

February 6th, 2020|

Monitoring minimal residual disease in the bone marrow using next generation sequencing

VIEW PUBLICATION ⟶

January 17th, 2020|

Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequence

VIEW PUBLICATION ⟶

November 13th, 2019|

Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications

VIEW PUBLICATION ⟶

October 15th, 2019|

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

VIEW PUBLICATION ⟶

October 1st, 2019|

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

VIEW PUBLICATION ⟶

June 6th, 2019|

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

VIEW PUBLICATION ⟶

March 21st, 2019|

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

VIEW PUBLICATION ⟶

August 25th, 2018|

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

VIEW PUBLICATION ⟶

August 22nd, 2018|

Clinical-scale Rapid Autologous BK-virus Specific T Cell Line generation from Kidney Transplant Recipients with Active Viremia for Adoptive Immunotherapy

VIEW PUBLICATION ⟶

November 11th, 2017|

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

VIEW PUBLICATION ⟶

August 9th, 2017|

Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia

VIEW PUBLICATION ⟶

July 3rd, 2017|

In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis

VIEW PUBLICATION ⟶

June 20th, 2017|

Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients

VIEW PUBLICATION ⟶

June 17th, 2017|

T and B cell clonal expansion in Ras associated lymphoproliferative disease (RALD) as revealed by next generation sequencing

VIEW PUBLICATION ⟶

May 30th, 2017|

Molecular pathology diagnosis of diffuse large B cell lymphoma using BIOMED-2 clonal gene rearrangements

VIEW PUBLICATION ⟶

April 27th, 2017|

A Small Case Series of Intravascular Large B-Cell Lymphoma with Unexpected Findings: Subset of Cases with Concomitant Extravascular Central Nervous System (CNS) Involvement Mimicking Primary CNS Lymphoma

VIEW PUBLICATION ⟶

April 17th, 2017|

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

VIEW PUBLICATION ⟶

October 31st, 2016|

Breast Implant-Associated Anaplastic Large Cell Lymphoma: Two Distinct Clinicopathological Variants with Different Outcomes

VIEW PUBLICATION ⟶

February 1st, 2016|

Archived Publications

Discordant Lymphoma Consisting of Mediastinal Large B-Cell Lymphoma and Nodular Sclerosis Hodgkin Lymphoma in the Right Supraclavicular Lymph Nodes: A Case Report

VIEW PUBLICATION ⟶

December 29th, 2015|

Molecular Genetic Data Favoring a Sequential Clonal Transformation of a Large B Cell Lymphoma into an Anaplastic Large T Cell Lymphoma, ALK-Negative

VIEW PUBLICATION ⟶

December 1st, 2015|

Mucosal CD30-Positive T-Cell Lymphoproliferative Disorder Arising in the Oral Cavity Following Dental Implants

VIEW PUBLICATION ⟶

August 10th, 2015|

Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia

VIEW PUBLICATION ⟶

March 18th, 2015|

Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas

VIEW PUBLICATION ⟶

August 15th, 2014|

Immunoblastic Follicular Lymphoma: A Very Unusual Transformation of Low-Grade Follicular Lymphoma

VIEW PUBLICATION ⟶

August 13th, 2014|

The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies

VIEW PUBLICATION ⟶

April 5th, 2014|

Clonality Of Multiple Distinct Lymphoproliferative Disorders Occurring Within Individual HIV+ Patients

VIEW PUBLICATION ⟶

November 15th, 2013|

Hydroa Vacciniforme-like Lymphoma: A Chronic EBV+ Lymphoproliferative Disorder with Risk to Develop a Systemic Lymphoma

VIEW PUBLICATION ⟶

October 31st, 2013|

Paediatric and Adolescent Elevated Conjunctival Lesions in the Plical Area: Lymphoma or Reactive Lymphoid Hyperplasia?

VIEW PUBLICATION ⟶

October 25th, 2013|

Diagnostic Utility of a Clonality Test for Lymphoproliferative Diseases in Koreans Using the BIOMED-2 PCR Assay

VIEW PUBLICATION ⟶

October 25th, 2013|

Dried Blood Spot Sampling for Detection of Monoclonal Immunoglobulin Gene Rearrangement

VIEW PUBLICATION ⟶

August 13th, 2013|

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations

VIEW PUBLICATION ⟶

October 26th, 2012|

A Practical Approach to Diagnostic Ig/TCR Clonality Evaluation in Clinical Pathology

VIEW PUBLICATION ⟶

January 11th, 2012|

Multiple Clonal Ig/TCR Products: Implications for Interpretation of Clonality Findings

VIEW PUBLICATION ⟶

December 10th, 2011|

Application of cost–effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia

VIEW PUBLICATION ⟶

March 30th, 2011|

Molecular Diagnostics of Hematologic Malignancies

VIEW PUBLICATION ⟶

September 2nd, 2009|

IMGT/GeneInfo: T cell receptor gamma TRG and delta TRD genes in database give access to all TR potential V(D)J recombinations

VIEW PUBLICATION ⟶

April 26th, 2006|

IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V–J and V–D–J JUNCTIONs

VIEW PUBLICATION ⟶

August 4th, 2004|

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Publications

Publications

FEATURED PUBLICATIONS

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Leveraging Standardized MRD Assays to Guide CLL Treatment

LATEST PUBLICATIONS

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Leveraging Standardized MRD Assays to Guide CLL Treatment

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL

Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx

Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform

Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing

Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma

Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers

Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Plasticity of the human IgM repertoire in response to long‐term spaceflight

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment

Evaluation of the polymerase chain reaction–based T-cell receptor β clonality test in the diagnosis of early mycosis fungoides

Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status

Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complications

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

Monitoring minimal residual disease in the bone marrow using next generation sequencing

Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequence

Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Clinical-scale Rapid Autologous BK-virus Specific T Cell Line generation from Kidney Transplant Recipients with Active Viremia for Adoptive Immunotherapy

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia

In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis

Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.